An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists
References (72)
- et al.
Selected drug complications and treatment conflicts in the presence of coexistent diseases
Rheum Dis Clin North Am.
(1999) - et al.
Performance of community pharmacy drug interaction software
J Am Pharm Assoc (Wash).
(2001) - et al.
The role of pharmacy computer systems in preventing medication errors
J Am Pharm Assoc (Wash).
(2002) - et al.
Chloroquine-digoxin interaction
IntJ Pharmaceut.
(1985) A reaction between capto-pril (a high blood pressure drug) and gold(I)-thiomalate
J Inorg Biochem.
(1987)- et al.
Mechanism of angio-tensin converting enzyme inhibitor-related anemia in renal transplant recipients
Kidney Int.
(1996) - et al.
Prevalence and management of anemia in renal transplant recipients: A European survey
Am J Transplant.
(2003) - et al.
Lack of a significant adverse cardiovascular effect of combined quinine and meflo-quine therapy for uncomplicated malaria
Trans R Soc Trop Med Hyg.
(1997) - et al.
Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline
J Allergy Clin Immunol.
(1991) - et al.
Fatal hepatitis with leflunomide and itraconazole
Am J Med.
(2002)
Drug-drug interactions related to hospital admissions in older adults: A prospective study of 1000 patients
J Am Geriatr Soc.
Drug-drug interactions among elderly patients hospitalized for drug toxicity
JAMA.
Clinically important drug interactions with disease-modifying antirheumatic drugs
Drugs Aging.
Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis
Br J Rheumatol.
Slow-acting antirheumatic drugs. Drug interactions of clinical significance
Drug Saf.
Comparative assessment of four drug interaction compendia
Br J Clin Pharmacol.
Pharmacist recognition of potential drug interactions
Am J Health Syst Pharm.
Improving recognition of drug interactions: Benefits and barriers to using automated drug alerts
Med Care.
Evaluation of personal digital assistant software for drug interactions
Am J Health Syst Pharm.
GPs' views on computerized drug interaction alerts: Questionnaire survey
J Clin Pharm Ther.
Clinical relevance of drug-drug interactions: A structured assessment procedure
Drug Saf.
PubMed
EMBASE.com
Inter-rater agreement
Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol
Clin Pharmacol Ther.
Allopurinol-azathioprine interaction
J Intern Med.
Clinico-pathologic correlation of liver damage in patients treated with 6-mercaptopurine and Adria-mycin
Cancer.
Effect of azathioprine on the anticoagulant activity of warfarin in patients with the antiphos-pholipid syndrome
Arthritis Rheum.
Azathioprine and inhibition of the anticoagulant effect of warfarin: Evidence from a case report and a literature review
Am J Geriatr Pharmacother.
The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans
Biopharm Drug Dispos.
The effect of penicillamine on serum digoxin levels
Jpn Heart J.
Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate
Clin Pharmacol Ther.
Digoxin-hydroxychloroquine interaction?
Acta Med Scand.
The effect of activated charcoal and cholestyramine on the pharmacokinetics of leflunomide
Clin Pharmacol Ther.
Cited by (29)
Encapsulation of Ginger Extract in Nanoemulsions: Preparation, Characterization and in vivo Evaluation in Rheumatoid Arthritis
2023, Journal of Pharmaceutical SciencesNanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy
2019, Journal of Controlled ReleaseCitation Excerpt :Besides their clinical significance in disease remission, DMARDs have also been associated with mild (nausea, vomiting, rashes, stomatitis) to severe life threatening infections, which alarm regular monitoring of DMARDs inclusive therapy. Conventional DMARDs may cause severe gastrointestinal problems, neutropenia, bone marrow suppression, intestinal-lung diseases, severe hepatotoxicity, nephrotoxicity, pneumonia, and liver cirrhosis [39,40]. Although, the use of conventional pharmacological agent results in therapeutic effects up to a certain extent; however, their long-term use or dose escalation may cause life-threatening adverse effects.
Practical Pearls About Current Rheumatic Medications
2018, Primary Care - Clinics in Office PracticeCitation Excerpt :Folic or folinic acid supplementation reduces the methotrexate-associated gastrointestinal, hepatic, and mucositis side effects but not hematologic toxicity.51 Significant drug-drug interactions between DMARDs and nonrheumatic medications are found in Table 8.52 The highest profile risk of antimalarial use is retinal toxicity.
Bezafibrate-mizoribine interaction: Involvement of organic anion transporters OAT1 and OAT3 in rats
2016, European Journal of Pharmaceutical SciencesCitation Excerpt :Rheumatoid arthritis is a chronic inflammatory disease primarily targeting the synovial membrane of the joints (Feely et al., 2009). Aged patients with rheumatoid arthritis are at risk of DDIs because of the multiple co-medications that might be taken as a consequence of the co-morbid conditions (Feely et al., 2009; van Roon et al., 2009). Despite some beneficial effects of the interactions (Cundy et al., 1995), accumulating evidences suggested that the DDIs could lead to more deleterious consequences such as toxicity or lack of efficacy for the substrate (Alsheikh-Ali et al., 2004; Endres et al., 2006).
In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate
2011, European Journal of Pharmaceutical SciencesCitation Excerpt :Rheumatoid arthritis is a chronic inflammatory disease that primarily targets the synovial membrane of the joints (Feely et al., 2009). Patients with rheumatoid arthritis are at risk of drug–drug interactions (DDIs) because of the multiple co-medications that might be taken as a consequence of the co-morbid conditions that could be present due to their advanced age (Feely et al., 2009; van Roon et al., 2009). In addition, efficacy studies in rheumatoid arthritis patients, performed as part of the clinical development program for a new candidate drug for the treatment of rheumatoid arthritis, are carried out on a background of concurrent active therapies, such as steroids, nonsteroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs) (US Food and Drug Administration (FDA) Treatment of rheumatoid arthritis guidance, 1999), and thus a DDI with the candidate drug could ensue.
Integration of Clinical and Scientific Principles in the Teaching of Drug-Drug Interactions
2021, Medical Science Educator